Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent endometrial cancer.
Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.
More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial…
Fred Hutch graduate student Adam Nguyen has won a F31 training award from the NIH to study a complex molecule called Tie2 that aids and…
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Physician, Scientist, Industry (Non-Exhibitor), PhD, Other $749 Resident/Student, Fellow,…
Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.
More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial…
Issa Khouri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the addition of inotuzumab ozogamicin to a reduced-intensity…
Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.
AACR’s 2024 Cancer Progress Report and Cancer Disparities Progress Report shared insights into advances and challenges in cancer research.
